BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare CNS Disease Analysis: Depression

December 16, 2020

The drug market for depression is projected to expand in the next 10 years, propelled by a growing patient caseload and uptake of new products approved for indications beyond major depressive disorder (MDD), including post-partum depression (PPD), treatment-resistant depression (TRD), and suicidal ideation.

The primary distinguishing factor in the depression market is a drug’s ability to satisfy unmet needs. The latest market entrants, Spravato and Zulresso, have appeared highly attractive in their capacity to fulfill needs through their approvals for difficult-to-treat patient populations coupled with their refreshing first-in-class mechanisms. Novelty in mechanism of action is a key differentiator that has finally reached the depression market after decades of stagnated innovation, since long-standing standard-of-care drug classes have been inadequate in treating depression. Traditional therapies may take four to six weeks to produce clinically meaningful effects, and refractory depression persists.

This Datamonitor Healthcare report contains a Disease Analysis module.
 

Indications Covered: Major Depressive Disorder (MDD)
Back to the top Back to the top